MA46896A - Composés d'alcène tétrasubstitués et leur utilisation - Google Patents
Composés d'alcène tétrasubstitués et leur utilisationInfo
- Publication number
- MA46896A MA46896A MA046896A MA46896A MA46896A MA 46896 A MA46896 A MA 46896A MA 046896 A MA046896 A MA 046896A MA 46896 A MA46896 A MA 46896A MA 46896 A MA46896 A MA 46896A
- Authority
- MA
- Morocco
- Prior art keywords
- alcene
- tetrasubstituted
- compounds
- tetrasubstituted alcene
- alcene compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641040208 | 2016-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46896A true MA46896A (fr) | 2019-10-02 |
Family
ID=60923887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046896A MA46896A (fr) | 2016-11-24 | 2017-11-22 | Composés d'alcène tétrasubstitués et leur utilisation |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190337921A1 (fr) |
| EP (1) | EP3544956A1 (fr) |
| JP (1) | JP2019535781A (fr) |
| CN (1) | CN110267940A (fr) |
| MA (1) | MA46896A (fr) |
| WO (1) | WO2018098251A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3122621A1 (fr) * | 2018-12-17 | 2020-06-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antagoniste du recepteur des strogenes |
| MX2021015486A (es) | 2019-06-19 | 2022-01-24 | Jiangsu Hengrui Medicine Co | Derivado de indazol, metodo de preparacion y aplicacion farmaceutica del mismo. |
| CN116615418B (zh) * | 2020-12-18 | 2025-11-11 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| CN114644616B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法 |
| CN114644615B (zh) * | 2020-12-18 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种吲唑类衍生物的结晶形式及其制备方法 |
| AU2021413598A1 (en) * | 2020-12-30 | 2023-07-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt form of tetra-substituted olefin compound, crystal, and preparation method therefor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60013114T2 (de) * | 1999-05-04 | 2005-08-18 | Wyeth | 3,3-substituerte indolinderivate |
| WO2009120999A2 (fr) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Utilisation d’un promédicament d’endoxifène dans le traitement du cancer de la poitrine |
| WO2011129837A1 (fr) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Emploi d'un promédicament de type 4-hydroxytorémifène dans le traitement du cancer du sein |
| GB2483736B (en) * | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| GB201311891D0 (en) * | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| SG11201607334YA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| EP3302471B1 (fr) * | 2015-05-29 | 2021-08-25 | Eisai R&D Management Co., Ltd. | Composés d'alcènes tétrasubstitués et leur utilisation |
-
2017
- 2017-11-22 MA MA046896A patent/MA46896A/fr unknown
- 2017-11-22 JP JP2019528139A patent/JP2019535781A/ja active Pending
- 2017-11-22 US US16/349,508 patent/US20190337921A1/en not_active Abandoned
- 2017-11-22 EP EP17825312.6A patent/EP3544956A1/fr not_active Withdrawn
- 2017-11-22 CN CN201780082789.1A patent/CN110267940A/zh active Pending
- 2017-11-22 WO PCT/US2017/062978 patent/WO2018098251A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018098251A1 (fr) | 2018-05-31 |
| JP2019535781A (ja) | 2019-12-12 |
| CN110267940A (zh) | 2019-09-20 |
| US20190337921A1 (en) | 2019-11-07 |
| EP3544956A1 (fr) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43364A (fr) | Composés d'alcènes tétrasubstitués et leur utilisation | |
| MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
| MA47440A (fr) | Sulfonylurées, composés apparentés, et leur utilisation | |
| EP3373969A4 (fr) | Composés interagissant avec le glycane et méthodes d'utilisation | |
| MA45709A (fr) | Composés diazahétérobicycliques substitués et leur utilisation | |
| EP3504213A4 (fr) | Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation | |
| EP3429635A4 (fr) | Composés anti-crispr et leurs procédés d'utilisation | |
| EP3430731A4 (fr) | Architecture d'iugw | |
| MA43827A (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| EP3411035A4 (fr) | Composés aminothiazole et leur utilisation | |
| EP3464313A4 (fr) | Nucléotides modifiés 5 '-cyclo-phosphonate | |
| MA45613A (fr) | Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique | |
| MA45113A (fr) | Composés mic-1 et leur utilisation | |
| EP3303435A4 (fr) | Hydrofluoroléfines et procédés d'utilisation associés | |
| MA46896A (fr) | Composés d'alcène tétrasubstitués et leur utilisation | |
| EP3717462A4 (fr) | Composés de sulfonamide et leur utilisation | |
| EP3336091A4 (fr) | Inhibiteur d'irak4 et son utilisation | |
| MA39915B1 (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| EP3008124A4 (fr) | Compositions d'amidon et leur utilisation | |
| MA46422A (fr) | Oligonucléotides modifiés et méthodes d'utilisation | |
| MA50440A (fr) | Imidazopyridinamides substituées et leur utilisation | |
| MA41642A (fr) | Variants de protoxine ii et méthodes d'utilisation | |
| EP2953938A4 (fr) | Composés de benzopyrane fonctionnalisés et leur utilisation | |
| EP3434666A4 (fr) | Dérivé d'arylamine et utilisation correspondante |